ARO-APOC3

Generic Name: ARO-APOC3

Drug Type: Biotech

Background: ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.

Clinical Trials

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Phase 3

Not yet recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Plozasiran
Drug: Placebo

First Posted Date: 2025-03-18

Last Posted Date: 2025-03-18

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT06880770

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Phase 3

Not yet recruiting

Conditions: Hypertriglyceridemia

Interventions: Drug: Plozasiran Injection

First Posted Date: 2025-02-12

Last Posted Date: 2025-02-12

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 840

Registration Number: NCT06822790

Treatment Protocol of Plozasiran in Adults With FCS

Conditions: Familial Chylomicronemia

First Posted Date: 2025-01-28

Last Posted Date: 2025-01-28

Lead Sponsor: Arrowhead Pharmaceuticals

Registration Number: NCT06796426

Locations: 🇺🇸
Arrowhead Pharmaceuticals, Inc., Pasadena, California, United States

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Hypertriglyceridemia

Interventions: Drug: Placebo
Drug: Plozasiran Injection

First Posted Date: 2024-04-04

Last Posted Date: 2025-03-25

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 1328

Registration Number: NCT06347133

Locations: 🇺🇸
University of Louisville Research Foundation, Louisville, Kentucky, United States
🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸
Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States

and more 228 locations

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Plozasiran Injection
Drug: Placebo

First Posted Date: 2024-04-04

Last Posted Date: 2025-03-26

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06347016

Locations: 🇺🇸
Ascension St. Vincents Birmingham, Birmingham, Alabama, United States
🇺🇸
IMC-Diagnostic and Medical Clinic LLC, Mobile, Alabama, United States
🇺🇸
National Heart Institute, Beverly Hills, California, United States

and more 145 locations

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Plozasiran Injection
Drug: Placebo

First Posted Date: 2024-04-04

Last Posted Date: 2025-03-18

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 405

Registration Number: NCT06347003

Locations: 🇺🇸
Andres Garcia Zuniga MD PA, Laredo, Texas, United States
🇧🇪
De Meulemeester, Marc, Gozée, Belgium
🇧🇪
Jesse Ziekenhuis, Hasselt, Belgium

and more 193 locations

Study of ARO-APOC3 in Adults With Dyslipidemia

Phase 2

Active, not recruiting

Conditions: Dyslipidemias

Interventions: Drug: ARO-APOC3

First Posted Date: 2022-06-09

Last Posted Date: 2025-01-07

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 418

Registration Number: NCT05413135

Locations: 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸
Valley Clinical Trials; Inc., Northridge, California, United States
🇺🇸
Desert Medical Group, Inc., Palm Springs, California, United States

and more 57 locations

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Phase 3

Active, not recruiting

Conditions: Familial Chylomicronemia

Interventions: Drug: Placebo
Drug: Plozasiran

First Posted Date: 2021-10-22

Last Posted Date: 2025-04-30

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 75

Registration Number: NCT05089084

Locations: 🇵🇱
Instytut Centrum Zdrowia Matki Polki, Łódź, Poland
🇺🇸
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇺🇸
Ascension St. Vincent Cardiovascular Research Institute, Indianapolis, Indiana, United States

and more 55 locations

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia

Phase 2

Completed

Conditions: Mixed Dyslipidemia

Interventions: Drug: ARO-APOC3
Drug: Placebo

First Posted Date: 2021-08-10

Last Posted Date: 2024-04-18

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 353

Registration Number: NCT04998201

Locations: 🇺🇸
Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States
🇺🇸
Preventive Cardiology Inc., Boca Raton, Florida, United States
🇺🇸
A & R Research Group, Pembroke Pines, Florida, United States

and more 27 locations

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Phase 2

Completed

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Placebo
Drug: ARO-APOC3

First Posted Date: 2021-01-22

Last Posted Date: 2024-04-18

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 229

Registration Number: NCT04720534

Locations: 🇺🇸
Pioneer Research Solutions, Inc., Houston, Texas, United States
🇺🇸
Clinical Research of South Nevada, Las Vegas, Nevada, United States
🇺🇸
AppleMed Research Group, Miami, Florida, United States

and more 71 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy